Decades of History Tell Anything: Biotech Near $50 Set to Soar
A cash-generative biotech near $50 is drawing buyers amid a market shift toward defensible healthcare names. Here’s w...
Using a home equity loan for debt payoff can be a smart strategy. Understand how it works to make informed choices.
19,606 articlesA cash-generative biotech near $50 is drawing buyers amid a market shift toward defensible healthcare names. Here’s w...
SpaceX reportedly trims its IPO ambitions, signaling a lower target valuation looming. This article breaks down what ...
Markets paused their march higher at midday as tech leadership shines and geopolitical headwinds test appetite. Marve...
Anthropic's public listing signals a new wave of AI investment. This piece highlights which major tech names could ri...
A major AI and cloud deal is flanking SpaceX's IPO, potentially nudging investor sentiment. This article breaks down ...
When a judge dismisses trafficking battery claims, the immediate liability may fade, but the financial impact lingers...
SpaceX's much-anticipated IPO is expected to deliver a first-day surge that could surpass historic records. Valued ar...
Tech shares lead a broad market rally as a truce between Iran and the United States reduces geopolitical risk, liftin...
As markets enter the midyear phase of 2026, three proven compounders highlight why patient investing still works. App...
Cardano faces a pivotal test as founder Charles Hoskinson lays out a four-layer rescue plan blending governance refor...
Investors are moving past SpaceX hype toward proven AI cash generators. This report explains why NVIDIA stands out as...
Marvell Technology has staged a decisive run in 2026, outpacing Broadcom in the AI accelerator stock race. As data-ce...